Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins
NCT01189877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2012-10-11
Summary
The purpose of this study is to see if the cells in rectal cancer are oxygen-starved, or hypoxic. We know that as cancers grow bigger, parts of them are cut off from the oxygen supply and they become hypoxic, basically, lacking oxygen. Research has shown that cells that are oxygen-starved respond differently to treatment such as chemotherapy and radiation when compared to cells that are oxygen rich.
Conditions
Interventions
- PROCEDURE
-
Eppendorf hypoximeter
Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
José Guillem, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 89 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
NCT00077259 ·Status: COMPLETED ·Phase: PHASE2
-
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02368886 ·Status: COMPLETED ·Phase: PHASE2
-
Escalated Dose of Irinotecan in mCRC
NCT02256800 ·Status: COMPLETED ·Phase: NA
-
Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
NCT02280694 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00258232 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
NCT07263178 ·Status: RECRUITING
-
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
NCT01282502 ·Status: COMPLETED ·Phase: PHASE1
-
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
NCT00608595 ·Status: TERMINATED ·Phase: NA
-
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
NCT06195670 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01280643 ·Status: TERMINATED ·Phase: NA
-
A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
NCT04227041 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746 ·Status: RECRUITING ·Phase: PHASE1
-
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
NCT00506571 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT00030797 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
NCT03380689 ·Status: WITHDRAWN ·Phase: PHASE1
-
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
NCT02437071 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
NCT00838578 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
NCT02211443 ·Status: UNKNOWN ·Phase: PHASE1
-
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
NCT00250029 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
NCT05818267 ·Status: RECRUITING ·Phase: NA
-
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
NCT00230399 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00559676 ·Status: COMPLETED ·Phase: PHASE4
-
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT05731726 ·Status: RECRUITING ·Phase: PHASE2
-
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
NCT00557102 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study Of The ERCC-1 Gene
NCT00846482 ·Status: COMPLETED ·Phase: NA